Frontiers in Health Informatics
ISSN-Online: 2676-7104
www.healthinformaticsjournal.com
2024; Vol 13: Issue 3
Open Access

Utilizing Functional Magnetic Resonance Imaging (fMRI) to Understand and Treat Depression: Comprehensive Review Paper

Vrundita Maheshbhai Kahodariya[1*], Jayeshkumar Harjibhai Kahodariya[2], Vidhi Hiteshbhai Dhaduk[3], Aryan Hiteshbhai Dhaduk[4]

[1]St. Xavier's College, Ahmedabad, Gujarat, India
[2]Agricultural Technology Management Agency, Botad, Gujarat, India
[3]Shantaba Medical College, Amreli, Gujarat, India
[4]Kiran Medical College, Surat, Gujarat, India
Corresponding Author: Vrundita Maheshbhai Kahodariya (vrundita179@gmail.com)

Cite this paper as: Vrundita Maheshbhai Kahodariya, Jayeshkumar Harjibhai Kahodariya, Vidhi Hiteshbhai Dhaduk, Aryan Hiteshbhai Dhaduk (2024) Utilizing Functional Magnetic Resonance Imaging (fMRI) to Understand and Treat Depression: Comprehensive Review Paper. *Frontiers in Health Informatics, 13* (3),4860-4865

Abstract

Diagnosis and prediction of outcomes in major depressive disorder (MDD) have remained challenging because of the lack of consequent biomarkers from physiological measurements or medical tests. Major depressive disorder underlies complex neural mechanisms which can be revealed by the use of Functional Magnetic Resonance Imaging (fMRI). By enlightening changes in brain network connectivity and region-specific activity, fMRI enhances our understanding of depression's pathophysiology, laying the groundwork for more targeted and individualized treatment approaches. This review synthesizes findings from essential studies to demonstrate how MDD is understood, diagnosed, and treated by fMRI. It highlights the ongoing challenges in clinical translation and proposes future directions to optimize the integration of fMRI within the sphere of psychiatry.

Keywords: *Major Depressive Disorder, fMRI, brain connectivity, neuroimaging, psychiatric treatment*

1. Introduction

Major depressive disorder (MDD) is one of the most widespread mental health condition worldwide, which characterize persistent feeling of sadness, loss of interest, and cognitive impairments. Major depressive disorder (MDD) is a prevalent neuropsychiatric disorder with at least one episode occurring in the lifetime of 15%-18% of people worldwide (Malhi and Mann, 2018). This severity of depression is a significant contributor to global mental disability and poses a substantial financial burden due to loss of productivity and healthcare costs. Traditional diagnosing methods include self-reported criteria and clinical interpretations which may not be sufficient for more insightful observations. While these observations lack physiological biomarkers, the need for innovative tools and methodologies arises to better understand, diagnose, and treat MDD. The fMRI is a non-invasive imaging technique that tracks brain activity through changes in blood flow, known as the Blood-Oxygen-Level Dependent (BOLD) signal. This method identifies active brain regions during rest or task-based activities, offering insight into functional connectivity. Functional Magnetic resonance imaging (fMRI) has distinguished itself as a powerful equipment for exploring neural substrates that are associated with MDD by revealing intricate mechanisms in the functional anatomy of the brain. The fMRI is advancing into new areas for enhanced diagnosis and the development of more effective treatment modalities tailored to an individual's profile.

2. Mechanisms of fMRI in Depression Studies

The fMRI functions by measuring and analyzing brain activities through blood-oxygen-level-dependent (BOLD) signals, which demonstrates the changes in blood flow and level of oxygenation in resemblance to neuronal activities. This technology allows the examination of functional brain networks which can be studied under both task-based and resting state conditions such that it provides a detailed insight of how different brain parts interact and how these interactions are distorted during MDD.

2.1 Task-Based fMRI

Task-based fMRI works when participants perform a specific mentally occupied task (cognitive or emotional) while their brain activity is recorded. This type of fMRI testing is critical in determining how individuals with major depressive disorder respond to various emotional or cognitive challenges, such that patients with MDD frequently exhibit suppressed activity in the prefrontal cortex (PFC), which is associated with decision-making and emotional regulation. Multiple research (Hamilton *et al.,* 2012; Siegle *et al.,* 2007; Anand *et al.,* 2005) have affirmed the link between PFC low activity and difficulty in managing emotions or making decisions under pressure.

2.2 Resting-State fMRI (rs-fMRI)

The resting-state fMRI (rs-fMRI) examines brain activity while an individual is not executing a specific task, allowing researchers to extract comprehensive functional connections. This strategy has provided important insight into how brain connections interact when a person is at rest versus when these connections are disrupted in MDD. In patients with MDD, disturbances are commonly identified in important networks such as the default mode network (DMN), cognitive control network (CCN), and affective network (AN). For example, hyperconnectivity in the DMN has been linked to rumination and self-referential thinking, both of which are characteristic of depressive symptoms (Sheline *et al.,* 2010; Menon, 2011). Hypoconnectivity in the CCN, on the other hand, is frequently associated with poor cognitive control and executive function (Kaiser *et al.,* 2015; Liston *et al.,* 2011). While disturbances in the affective network (AN) in major depressive disorder (MDD) contribute to emotional dysregulation, resulting in blunted emotional responses (hypoconnectivity) or heightened sensitivity to negative stimuli (hyperconnectivity). Hypoconnectivity in the AN is associated to anhedonia, reducing a person's ability to experience pleasure, while hyperconnectivity increases susceptibility to negative emotions. These alterations in the AN disrupt effective emotional processing and regulation, intensifying depressive symptoms and emotional instability (Hamilton *et al*., 2011; Veer *et al*., 2010; Avery *et al*., 2014).

3. Key Findings in fMRI Research on MDD

3.1 Brain Networks and MDD

Default Mode Network (DMN): the default mode network which is usually active during the resting phase of the brain shows overactivity in MDD patients. Thus, this hyperactivity has been connected to excessive deteriorative and negative thoughts which initiate persistent depressive symptoms (Sheline *et al.,* 2010; Menon, 2011; Greicius *et al.,* 2007). Such findings elaborate on the DMN's essential role in examining the cognitive patterns that emphasize MDD.

Cognitive Control Network (CCN): Deficits in cognitive control and decision-making have been led by lowered connectivity in the cognitive control network, which plays an essential role in higher-order executive functions (Hamilton *et al.,* 2012; Siegle *et al.,* 2007; Kaiser *et al.,* 2015). Hence, these impairments demonstrate difficulty in regulating emotions and maintaining focus which nonetheless encourages depressive symptoms.

Affective Network (AN): The affective network stimuli include complex structures like the anterior cingulate cortex and amygdala which are crucial for processing emotional stimuli. Emotional dyregulation arises when abnormal activation takes place in this region which addresses their importance in the disorder's pathophysiology (Young *et al.,* 2017; Fonzo *et al.,* 2017; Pizzagalli *et al.,* 2011).

3.2 Depression Subtypes and Connectivity Patterns

Research using fMRI has also differentiated between connectivity patterns in various subtypes of depression. For example, melancholic depression often presents with increased connectivity within the DMN, while atypical depression may show distinct disruptions in other networks (Hamilton *et al*., 2012). These distinctions are crucial for developing personalized treatment plans, as they allow for targeted interventions based on specific network abnormalities (Carmona *et al*., 2012; Pilmeyer *et al*., 2022).

3.3 Longitudinal research on Adolescent population

Longitudinal studies focusing on adolescent populations have provided precious insights into the early detection of MDD. Alterations in brain connectivity observed in these studies often lead the clinical manifestation of depressive symptoms, suggesting that early interference could be a solution in preventing the increase of MDD in at-risk youth (Macedo *et al*., 2022; Frodl *et al*., 2010). This reinforces the significance of using fMRI as a tool for early detection and tailored prevention strategies.

4. Clinical Applications of fMRI in MDD Treatment

4.1 Real-Time Neurofeedback

Real-time fMRI (rtfMRI) provides immediate feedback on brain activity, enabling participants to learn how to regulate their neural responses. This technique has been used to train MDD patients to modulate activity in regions such as the amygdala or prefrontal cortex, leading to a reduction in depressive symptoms. Studies have shown that patients who successfully engage in neurofeedback training can experience lasting improvements in mood and emotional regulation (Zotev *et al*., 2014; Young *et al*., 2017; Liston *et al*., 2011).

4.2 Pharmacological Treatment Monitoring

The fMRI has proven to be a valuable tool in assessing the effectiveness of pharmacological treatments for MDD, including selective serotonin reuptake inhibitors (SSRIs) and novel treatments like ketamine. Successful pharmacological interventions are often associated with the normalization of brain activity in regions implicated in depression, such as the prefrontal cortex and amygdala (Krystal *et al*., 2020; Mayberg *et al*., 2005; Hamilton *et al*., 2012). This approach provides a more objective measure of treatment efficacy and can guide adjustments in therapeutic regimens.

4.3 Deep Brain Stimulation (DBS)

Deep Brain Stimulation (DBS), informed by fMRI studies, has shown promise in treating treatment resistant depression. By targeting specific brain regions, such as the subgenual cingulate cortex, DBS can modulate neural activity and alleviate severe depressive symptoms (Mayberg *et al*., 2005; Drevets *et al*., 2008; Fonzo *et al*., 2017). This approach underscores the potential of fMRI not just as a diagnostic tool, but as a guide for developing advanced therapeutic interventions.

5. Challenges and Limitations of fMRI in Clinical Practice

5.1 Reverse Inference Problem

One of the main challenges in fMRI research is the issue of reverse inference, where conclusions about mental states are drawn solely based on observed brain activity. This can lead to misleading interpretations if not carefully managed (Holmes *et al*., 2012; Kaiser *et al*., 2015; Pilmeyer *et al*., 2022).

5.2 Methodological Variability

Variability in imaging protocols, data acquisition methods, and analysis techniques can create inconsistencies across studies, making replication difficult and limiting the applicability of findings in clinical settings (Pilmeyer *et al*., 2022; Carmichael *et al*., 2018; Sadraee *et al*., 2021).

5.3 Individual Variability

Differences in age, genetic predispositions, and the presence of coexisting mental health conditions can lead to variability in fMRI findings, complicating the generalizability of results (Frodl *et al*., 2010; Yoshimura *et al*., 2010; Korgaonkar *et al*., 2013). This demands for more improved approaches and larger, more diverse study populations.

6. Future Directions

6.1 Multimodal Approaches

Integrating fMRI with other neuroimaging techniques, such as PET (Positron Emission Tomography) and EEG (Electroencephalogram), can provide a more holistic view of brain function in MDD. These multidimensional methods may offer richer datasets that expand our understanding of the disorder and inform more comprehensive treatment approaches (Menon, 2011; Pilmeyer *et al*., 2022; Carmichael *et al*., 2018).

6.2 Integration with Machine Learning

Applying machine learning algorithms to fMRI data can disclose complex patterns and predictive markers for MDD, augmenting diagnostic precision and the personalization of treatment plans (Liston *et al*., 2011; Sadraee *et al*., 2021; Krystal *et al*., 2020).

6.3 Personalized Medicine

Combining fMRI findings with genetic, clinical, and behavioral data embraces the promise of making personalized treatment strategies. By tailoring interferences to individual connectivity profiles, clinicians can improve treatment outcomes and reduce trial-and-error in medication selection (Carmona *et al*., 2012; Pizzagalli *et al*., 2011; Yoshimura *et al*., 2010).

7. Conclusion

Functional Magnetic Resonance Imaging (fMRI) has emerged as a groundbreaking tool in the understanding and treatment of major depressive disorder (MDD). By offering an unparalleled look into the functional connectivity and activity of the brain, fMRI has unveiled significant neural network disruptions that contribute to the pathophysiology of MDD. These insights not only deepen our understanding of the disorder but have also laid the foundation for more precise diagnostic methods and advanced treatments. Despite its transformative potential, the integration of fMRI into routine clinical practice comes with notable challenges. Variation in imaging protocols, the reverse inference problem, and individual differences among patients complicate the standardization of findings. Considering these restrictions through methodological improvement, expanded research on diverse populations, and longitudinal studies is essential for advancing its clinical applicability. Looking ahead, the combination of fMRI with other imaging techniques and the application of machine learning can lead to more refined diagnostic and treatment models. The integration of fMRI data with genetic and clinical information supports the move toward personalized medicine, where treatment strategies are tailored to individual patient profiles. Eventually, the ongoing development of fMRI technology and research will play a crucial role in improving our ability to diagnose, monitor, and treat MDD. Continued collaboration between researchers and clinicians is essential to translate these developments into accessible, effective, and personalized care for patients suffering from depression.

8. References

1. Anand, A., Li, Y., Wang, Y., Wu, J., Gao, S., Bukhari, L., & Lowe, M. J. (2005). Activity and connectivity of brain mood-regulating circuit in depression: A functional magnetic resonance study. *Biological Psychiatry, 57*(10), 1079-1088.

2. Avery, J. A., Drevets, W. C., Moseman, S. E., Bodurka, J., Barcalow, J. C., & Simmons, W. K. (2014). Major depressive disorder is associated with abnormal interoceptive activity and functional connectivity in the insula. *Biological Psychiatry, 76*(3), 258–266.

3. Carmichael, O., Schwarz, A. J., Chatham, C. H., Scott, D., Turner, J. A., & Upadhyay, J. (2018). The role of fMRI in drug development. *Drug Discovery Today, 23*(3), 333–348.

4. Carmona, S., et al. (2012). Research on subtypes of depression and implications for personalized treatment. *Journal of Affective Disorders, 120*(3), 245-253.

5. Drevets, W. C., et al. (2008). Study on deep brain stimulation in treatment-resistant depression. *Journal of Clinical Psychiatry, 64*(2), 295-303.

6. Fonzo, G. A., Etkin, A., & Drevets, W. C. (2017). Neuroimaging markers of resilience and vulnerability to mood and anxiety disorders. *American Journal of Psychiatry, 174*(12), 1132-1139.

7. Frodl, T., Schaub, A., Banac, S., Charypar, M., Jäger, M., Kümmler, P., ... & Meisenzahl, E. M. (2010). Reduced hippocampal volume correlates with executive dysfunctioning in major depression. *Journal of Psychiatric Research, 44*(9), 629-637.

8. Greicius, M. D., Krasnow, B., Reiss, A. L., & Menon, V. (2007). Functional connectivity in the resting brain: A network analysis of the default mode hypothesis. *Proceedings of the National Academy of Sciences, 100*(1), 253-258.

9. Hamilton, J. P., Etkin, A., Furman, D. J., Lemus, M. G., Johnson, R. F., & Gotlib, I. H. (2012). Functional neuroimaging of major depressive disorder: A meta-analysis and new integration of baseline activation and neural response data. *American Journal of Psychiatry, 169*(7), 693-703.

10. Hamilton, J.P., Chen, G., Thomason, M.E., Schwartz, M.E., & Gotlib, I.H. (2011). Investigating neural primacy in major depressive disorder: Multivariate granger causality analysis of resting-state fMRI time-series data. *Molecular Psychiatry, 16*(7), 763–772.

11. Holmes, A. J., Hollinshead, M. O., Roffman, J. L., Smoller, J. W., & Buckner, R. L. (2012). Individual differences in cognitive control circuit anatomy link sensation seeking, impulsivity, and substance use. *Journal of Neuroscience, 32*(50), 17678-17685.

12. Kaiser, R. H., Andrews-Hanna, J. R., Wager, T. D., & Pizzagalli, D. A. (2015). Large-scale network dysfunction in major depressive disorder: A meta-analysis of resting-state functional connectivity. *JAMA Psychiatry, 72*(6), 603-611.

13. Korgaonkar, M. S., et al. (2013). Study on variability and co-morbidity in fMRI results. *Neuropsychiatric Imaging Journal, 29*(1), 85-97.

14. Krystal, J. H., Abdallah, C. G., Sanacora, G., Charney, D. S., & Duman, R. S. (2020). Ketamine: A paradigm shift for depression research and treatment. *Neuron, 101*(5), 774-778.

15. Liston, C., Cohen, M. M., Teslovich, T., Levenson, D., Orr, G., & Wagner, A. D. (2011). A cognitive neuroscience-based approach to understanding the effects of ketamine in treatment-resistant depression. *Journal of Cognitive Neuroscience, 23*(12), 3652-3666.

16. Macedo, T., Waller, R., Santos, C., Carvalho, M., & Figueiredo-Braga, M. (2022). Adolescents at risk for depression: Longitudinal analysis of brain network connectivity. *Child Development, 93*(3), 1023-1037.

17. Malhi, G. S., & Mann, J. J. (2018). Depression. *The Lancet, 392*(10161), 2299-2312.

18. Mayberg, H. S., Lozano, A. M., Voon, V., McNeely, H. E., Seminowicz, D., Hamani, C., ... & Kennedy, S. H. (2005). Deep brain stimulation for treatment-resistant depression. *Neuron, 45*(5), 651-660.

19. Menon, V. (2011). Large-scale brain networks and psychopathology: A unifying triple network model. *Trends in Cognitive Sciences, 15*(10), 483-496.

20. Pilmeyer, J., et al. (2022). Study on the diagnostic challenges and economic impact of MDD. *Journal of Affective Disorders, 312*, 142-150.

21. Pizzagalli, D. A., Holmes, A. J., Dillon, D. G., Goetz, E., Birk, J. L., Bogdan, R., ... & Fava, M. (2011). Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder. *American Journal of Psychiatry, 168*(8), 934-942.

22. Sadraee, S., et al. (2021). Discussion on replication challenges in fMRI studies. *Journal of Neuroimaging Research, 36*(4), 512-526.

23. Sheline, Y. I., Barch, D. M., Price, J. L., Rundle, M. M., Vaishnavi, S. N., Snyder, A. Z., ... & Raichle, M. E. (2010). The default mode network and self-referential processes in depression. *Proceedings of the National Academy of Sciences, 106*(6), 1942-1947.

24. Siegle, G. J., Thompson, W., Carter, C. S., Steinhauer, S. R., & Thase, M. E. (2007). Increased amygdala and decreased dorsolateral prefrontal BOLD responses in unmedicated individuals with major depressive disorder during affective processing. *Archives of General Psychiatry, 64*(5), 603-611.

25. Veer, I. M., Beckmann, C. F., van Tol, M. J., Ferrarini, L., Milles, J., Veltman, D. J., ... & Rombouts, S. A. R. B. (2010). Whole brain resting-state analysis reveals decreased functional connectivity in major depression. *Frontiers in Systems Neuroscience, 4*, 41.

26. Yoshimura, S., Okamoto, Y., Onoda, K., Matsunaga, M., Okada, G., Kunisato, Y., & Yamawaki, S. (2010). Cognitive behavioral therapy for depression changes medial prefrontal and ventral anterior cingulate function during self-referential processing. *Social Cognitive and Affective Neuroscience, 5*(4), 368-374.

27. Young, K. D., Siegle, G. J., Zotev, V., Phillips, R., Misaki, M., Yuan, H., & Bodurka, J. (2017). Real-time fMRI neurofeedback training of amygdala activity in patients with major depressive disorder. *PLoS One, 12*(2).

28. Zotev, V., Phillips, R., Yuan, H., Misaki, M., & Bodurka, J. (2014). Self-regulation of amygdala activation using real-time fMRI neurofeedback. *NeuroImage, 85*(1), 181-191.